AstraZeneca will acquire all outstanding shares of France-based Amolyt for up to $1.05 billion, including an $800 million upfront payment and an additional $250 million contingent upon regulatory milestones. The transaction, pending customary closing conditions and regulatory approvals, is slated for completion by the end of the third quarter of 2024.
Since the creation of its Rare Disease unit following the $39 billion takeover of Alexion Pharmaceuticals in 2021, AstraZeneca has continued to snatch up rare disease drugmakers, picking up New Jersey-based Caelum Biosciences in September 2021 and Massachusetts-based LogicBio Therapeutics in October 2022.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.